bluebird bio Inc - ESG Rating & Company Profile powered by AI
This page displays a zero-cost Sustainability analysis for bluebird bio Inc. The SDG rating for bluebird bio Inc represents the company's reporting of the United Nations Sustainable Development Goals. Alternative companies in the rating industry group for bluebird bio Inc are displayed below.
bluebird bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 2.0, social score of 1.6 and governance score of 8.0.
3.9
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
... | ... | ... | |
1089 | bluebird bio Inc | 3.9 | Medium |
1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
1089 | Allogene Therapeutics Inc | 3.9 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does bluebird bio Inc have an accelerator or VC vehicle to help deliver innovation?
Does bluebird bio Inc disclose current and historical energy intensity?
Does bluebird bio Inc report the average age of the workforce?
Does bluebird bio Inc reference operational or capital allocation in relation to climate change?
Does bluebird bio Inc disclose its ethnicity pay gap?
Does bluebird bio Inc disclose cybersecurity risks?
Does bluebird bio Inc offer flexible work?
Does bluebird bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does bluebird bio Inc disclose the number of employees in R&D functions?
Does bluebird bio Inc conduct supply chain audits?
Does bluebird bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does bluebird bio Inc conduct 360 degree staff reviews?
Does bluebird bio Inc disclose the individual responsible for D&I?
Does bluebird bio Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does bluebird bio Inc disclose current and / or historical scope 2 emissions?
Does bluebird bio Inc disclose water use targets?
Does bluebird bio Inc have careers partnerships with academic institutions?
Did bluebird bio Inc have a product recall in the last two years?
Does bluebird bio Inc disclose incidents of discrimination?
Does bluebird bio Inc allow for Work Councils/Collective Agreements to be formed?
Has bluebird bio Inc issued a profit warning in the past 24 months?
Does bluebird bio Inc disclose parental leave metrics?
Does bluebird bio Inc disclose climate scenario or pathway analysis?
Does bluebird bio Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does bluebird bio Inc disclose the pay ratio of women to men?
Does bluebird bio Inc support suppliers with sustainability related research and development?
Does bluebird bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does bluebird bio Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is bluebird bio Inc involved in embryonic stem cell research?
Does bluebird bio Inc disclose GHG and Air Emissions intensity?
Does bluebird bio Inc disclose its waste policy?
Does bluebird bio Inc report according to TCFD requirements?
Does bluebird bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does bluebird bio Inc disclose energy use targets?
Does bluebird bio Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does bluebird bio Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for bluebird bio Inc
These potential risks are based on the size, segment and geographies of the company.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.